## Life Sciences Insurance

### **Application Form**



#### Notice To Applicant - Please Read Carefully

Any person who knowingly and with intent to defraud any insurance company or other person, files an application for insurance or statement of claim containing any materially false information or conceals for the purpose of misleading, information concerning any fact material thereto commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties, including but not limited to fines, denial of insurance benefits, civil damages, criminal prosecution and confinement in state prison.

You are to disclose in this form fully and faithfully all facts which you know or ought to know, otherwise you may receive nothing from this insurance contract.

Notice: This is an application for a claims made and reported policy and that the limit of liability under any policy to be issued in response hereto shall include both indemnity payments for claims and payment of claim and defense expenses, as defined in the policy.

Please note that the defense cost provision of the policy stipulates that the limits of liability may be completely exhausted by the cost of legal defense. Any deductible or retention shall apply to investigation expense and defense costs as well as indemnity.

All questions in this application must be answered truthfully and completely for all persons or organisations applying for insurance under this application. If a question or section is not applicable, please answer "N/A". If the answer to a question is none, state "None" or "O". If more space is required to answer a question completely, please provide a separate attachment and identify the question it responds to.

Before continuing, please attach copies of the following with this application:

- Detailed loss information for the last 5 years
- Copies of standard and 3 largest sales, service & license contracts or agreements
- If private, most recent financial statement
- Protocols and informed consent documents for active sponsored clinical trials
- Other materials as applicable

Ge	General Information						
1.	Name of Applicant						
2.	Please provide brief description of your operations.						
3.	Address						
4.	Mailing Address (if different from address stated above)						
5.	Website Address						
6.	Locations (if other than above)						
7.	All Named Insureds						
8.	Additional Insureds (explain relationship)						
9.	Any acquired subsidiaries in the last 5 years?  If <b>Yes</b> , please provide entity name and date acquired.	□Yes	□No				
10.	Applicant is  Individual Partnership Corporation Joint Venture LLC  Other (please describe)						
11.	Years in business?						
12.	Does applicant have a parent company?  If <b>Yes</b> , please provide name of company.	□Yes	□No				

13.	Has applicant operated under another name?	□Yes	□No
	If <b>Yes</b> , please provide full details.		
14.	Who are applicant's top 3 competitors?		
15.	Has the applicant filed for bankruptcy in the last seven years?	□Yes	□No
	If <b>Yes</b> , provide full details, including a brief description of the reason for filing, bankruptcy jurisdiction, court r identity and contact information of the trustee.	number a	nd
16.	Is the applicant or any shareholders, directors, officers, partners, or members thereof under any investigation for alleged criminal violations relating to your business?	□Yes	□No
17.	Is applicant in compliance with all applicable regulatory guidelines?	□Yes	□No
	If <b>No</b> , please provide details.		
18.	Has applicant been cited for any regulatory violations in the last 3 years?	□Yes	□No
	If <b>Yes</b> , please provide details.		
19.	Total projected domestic gross sales?	\$	
20.	Total projected non-domestic gross sales?	\$	
21.	Previous year gross sales?	\$	

	%		%
Single Source Prescription		Single Source Over the Counter	
Multi-Source / Generic Prescription		Multi-Source / Generic Over the Counter	
<u> </u>			
pecialty Breakdown			
	%		%
Cardiology / Vascular Diseases		Oncology	
Dental / Maxillofacial Surgery		Ophthalmology	
Dermatology / Plastic Surgery		Otolaryngology	
Endocrinology		Pediatrics / Neonatology	
Gastroenterology		Pharmacology / Toxicology	
Hematology		Psychiatry / Psychology	
Immunology / Infectious Diseases		Pulmonary / Respiratory Diseases	
Musculoskeletal		Rheumatology	
Nephrology / Urology		Trauma / Emergency Medicine	
Neurology		Obstetrics / Gynecology	
Other			
Other  Does applicant have any past, present following categories?  If <b>Yes</b> , provide details.	nt or planned association		□Yes □No
Does applicant have any past, present following categories?	nt or planned association  Association		□Yes □No  Association
Does applicant have any past, present following categories?  If <b>Yes</b> , provide details.		with substances in any of the	_100 _100
Does applicant have any past, present following categories?  If <b>Yes</b> , provide details.  Category	Association	with substances in any of the  Category	Association
Does applicant have any past, present following categories?  If <b>Yes</b> , provide details.  Category  Known Teratogen	Association  □Yes □No	with substances in any of the  Category  Vaccines	Association  Yes No
Does applicant have any past, present following categories?  If <b>Yes</b> , provide details.  Category  Known Teratogen  Known Mutagen	Association  Yes No  Yes No	Category Vaccines Animal Derived	Association  Yes No
Does applicant have any past, present following categories?  If Yes, provide details.  Category  Known Teratogen  Known Mutagen  Known Carcinogen	Association  Yes No  Yes No  Yes No	Category Vaccines Animal Derived Human Derived	Association  Yes No  Yes No
Does applicant have any past, present following categories?  If Yes, provide details.  Category  Known Teratogen  Known Mutagen  Known Carcinogen  Plant Derived	Association  Yes No  Yes No  Yes No  Yes No	Category Vaccines Animal Derived Human Derived Anti-Depressant	Association  Yes No Yes No Yes No
Does applicant have any past, present following categories?  If Yes, provide details.  Category  Known Teratogen  Known Mutagen  Known Carcinogen  Plant Derived  Birth Control	Association  Yes No  Yes No  Yes No  Yes No  Yes No  Yes No	Category Vaccines Animal Derived Human Derived Anti-Depressant Hormone	Association  Yes No Yes No Yes No Yes No Yes No
Does applicant have any past, present following categories?  If Yes, provide details.  Category  Known Teratogen  Known Mutagen  Known Carcinogen  Plant Derived  Birth Control  Weight Reduction	Association  Yes No  Yes No  Yes No  Yes No  Yes No  Yes No	Category Vaccines Animal Derived Human Derived Anti-Depressant Hormone	Association  Yes No Yes No Yes No Yes No Yes No

Section B - Drugs / Biologics R&D or Product Revenue Percentages

#### $\square$ Please tick here if N/A. Hematology and Pathology Anesthesiology Cardiovascular Immunology and Microbiology Clinical Chemistry and Clinical Toxicology Neurology Dental Obstetrical and Gynecological Ear, Nose, and Throat Ophthalmic Gastroenterology and Urology Orthopedic Physical Medicine General and Plastic Surgery General Hospital and Personal Use Radiology Other Does applicant have any past, present, or planned association with any of the following products? □Yes □No If Yes, provide details. Association Association Product **Product Breast Implants** Spinal Devices □Yes □No □Yes □No **IUD Devices** □Yes □No Animal Derived □Yes □No Pedicle Screws □Yes □No **Human Derived** □Yes □No Latex Gloves □Yes □No **DEHP** □Yes □No **Details Section D - Dietary Supplement Product Revenue Percentages** $\square$ Please tick here if N/A. **Product** Product Vitamin Concentrate, metabolite, constituent or extract Mineral **Enzymes** Herb or other botanical Medical foods (Prescription required) Amino acid Other

Section C - Medical Devices R&D or Product Revenue Percentages

1.	Please identify any of your product categories currently listed on the FDA's Dietary Supplement Warnings and Safety Information Site (http://www.cfsan.fda.gov/~dms/ds-warn.html) or similar regulatory database.							
2.	Do any of your products contain any ani	imal derived su	bstances?	□Yes	□No			
3.	Do any of your products make health cla	aims?		□Yes	□No			
	If <b>Yes</b> , which ones and have they been p	oublished in pee	er review publications?					
4.	Have any of your products ever fit the de If <b>Yes</b> , have pre-market safety reviews b			□Yes	□No			
5.	Have any of your products ever had an a regulatory agency?	active ingredien	at that would be defined as a drug by a	□Yes	□No			
	If <b>Yes</b> , what are they?							
Sec	ction E - Professional Service Revenu	ie Percentage	s					
	Please tick here if N/A.	or a contemp	-					
Se	ervice	%	Service	%				
	LIA Certified Lab Services ndicate type of lab services)		Product Recall / Withdrawal					
Pl	hase 1 Site Services		Clinical Site Management					
C	linical Trials Packaging		Equipment Installation / Maintenance / Sterilisation					
	linical Site Selection, Training, Ionitoring		Quality Systems & Regulatory Compliance					
C	ommunications & Publications		Sales & Marketing					
	ealth Management, Economic & Policy esearch		Software Development or Product Design					

Ir	Information Services / Databases Manufacturing / Distribution / Packaging / Mixing / Labelling					
Ir	nstitutional Review Board		Pharmacovigilance / Safety Surveillance			
P	re-clinical Services		Warehouse storage			
F	inancial Services (Please describe)		Other (Please explain)			
1.	Does applicant have formalised project	-planning policies a	nd procedures?	□Yes	□No	
2.	Does applicant have formalised client c	omplaint resolution	n policies and procedures?	□Yes	□No	
3.	Are any contracts past due or has a clie	nt stopped paying o	or asked for a refund or credit in the last 3 years?	□Yes	□No	
	If <b>Yes</b> , please provide details.					
4.	Total number of current contracts?					
5.	Any discontinued services within the last 10 years?					
	If <b>Yes</b> , please provide details.					
6.	Average dollar value of applicant's cont	racts?		\$		
	Average duration of applicant's contrac	ts?				
7.	Indicate largest client for upcoming pol	icy year, and includ	le contract amount / volume and duration.			
8.	What is the total value of the personal p	property of others a	t applicant's facilities?	\$		
	Details					
Sec	ction F - Drug Discovery Technology	R&D or Product	Revenue Percentages			
	Please tick here if N/A.					
В	ioinformatics %	Proteomic	% Genomics	%		
So	oftware	Software	Software			
Н	ardware	Hardware	Hardware			
D	ata	Data	Data			
О	ther		-			
Det	tails					

Section G - Research Institutions R	evenues /	Funding				
$\square$ Please tick here if N/A.						
Service	%	Service			%	
Product Licensing		Product Co	mmercialisatio	n		
Basic Research		Medical Pro	oduct Research			
Pre-clinical Testing		Non Medica	al Product Rese	earch		
Clinical Testing		Other				
Details						
		hutan Davanua Danaanta	<b></b>			
Section H - Supplier and/or Whole	sale Distri	outor Revenue Percenta	ges			
$\square$ Please tick here if N/A.						
Service	%	Service			%	
Drugs / Biologics		Medical D Software	evice Compone	ent Parts /		
Medical Devices		Drugs / Bi	ologic Ingredie	nts		
Dietary Supplements		Medical Pr Equipmen	roducts Manufa nt	acturing		
Active Ingredients		Medical P	roducts R&D E	quipment		
Other						
If you are a supplier of component require additional insured status o	_		-			Yes □No
Do you require indemnification for	r damages in	acluding defense cost?				Yes □No
Details						
Section I - Human Clinical Trials						
$\square$ Please tick here if N/A.						
Active Trials Currently Being Sponsored	d. (Include p	hase 4)				
Product Name & No. of New En Protocol Number Over Next Pol		Indication	Trial Phase	Country(ies)		Number of sites

1.	Number of expanded access / compassionate use participants anticipated in the coming policy term?		
2.	Total number of completed human clinical trials applicant sponsored in last 3 years		
3.	Total number of human participants enrolled in the last 3 years		
4.	Any clinical trials past, present, or planned involving minors?		
5.	Any clinical trials discontinued or suspended due to safety reasons?	□Yes	□No
	If <b>Yes</b> , please provide details.		
6.	What are the minimum standards for Clinical Investigator selection requirements?		
7.	Have any Clinical Investigators been cited for regulatory violations in connection with your trials?	□Yes	□No
	If <b>Yes</b> , please provide details.		
8.	Has applicant had any evidence of serious regulatory non-compliance or fraud by Clinical Investigators in connection with your trials in the past 5 years?	□Yes	□No
	If <b>Yes</b> , please provide details.		
9.	Number of clinical trial "For Cause Audits" conducted by applicant or regulatory agency in the last 5 years?		
10.	Do you provide Clinical Investigators with compensation other than charges for specific services rendered, such as enrollment bonuses, equity interest, etc.?	□Yes	□No
11.	What is the targeted reading grade level for your informed consent documents?		
12.	Does applicant require Clinical Investigators to test participants on their understanding of the informed consent document?	□Yes	□No
13.	Does applicant incorporate financial disclosures in the informed consent documents or process?	□Yes	□No
14.	What has been the maximum compensation applicant has offered trial participants?	\$	
15.	Who monitors compliance with the individual state and country clinical trial regulations?		
16.	Does applicant have formalised Clinical Trial Suspension SOP's in place?	□Yes	□No
17.	Do any of applicant's employees or sub-contractors provide direct patient care on applicant's behalf?	□Yes	□No
	Do they carry their own medical malpractice insurance?	□Yes	□No
18.	Does applicant ever act as both trial sponsor and clinical investigator?	□Yes	$\square$ No

19.	9. Does applicant provide material / product, or both, for clinical trials for trials you do not sponsor?				□Yes	□No
20.	Does applicant operate	applicant operate an in-patient facility?  , does applicant have an accredited emergency care facility?				
	If <b>Yes</b> , does applicant l	have an accredited en	nergency care facility?		□Yes	□No
21.	In the last 3 years have conducted by applicar		any study results without including of t the same findings?	her studies that were	□Yes	□No
	If <b>Yes</b> , please provide	details.				
22.	Does the applicant pub	olish all clinical trial re	esults?		□Yes	□No
23.	Is applicant in complia	nce with all applicabl	e regulatory guidelines?		□Yes	□No
	If <b>No</b> , please provide details.					
24.	4. Has applicant been cited for any regulatory violations in the last 3 years?					□No
If <b>Yes</b> , please provide details.						
Sec	tion J - Medical Staff	Profile				
	Please tick here if N/A.					
Н	ealth professionals	Specialty	Est. hours of direct patient interactions annually	No. of Applicant Employees	No. of Independe Contractor	
Pł	nysicians					
RI	Ns					
	PNs					
	narmacist					
	edical Technician					
	MTs					
Ot	hers (please describe)					
Sec	tion K - Legal					
1.	Does applicant have an	ny contracts that:				
	a. Assume the tort li	ability of another part	ty		□Yes	□No
	b. Does not limit damages to direct damages only					□No

	c. Does not extend Force Majeure to any and all events outside applicant's control	□Yes	□No
	d. Does not indicate a mutual hold harmless agreement	□Yes	□No
	If you answered <b>Yes</b> to any of the questions above, please explain.		
2.	Does applicant use a written contract or agreement with all clients, including changes?	□Yes	□No
3.	Does applicant's attorney review all contracts or agreements including changes prior to use?	□Yes	□No
4.	Are there formal incidents and claims escalation procedures in place?	□Yes	□No
5.	Are there formal procedures in place regarding litigation document control?	□Yes	□No
6.	Is there formal training on internal and external communication policies and procedures?	□Yes	□No
Sec	ction L - Product Sales & Marketing		
	Please tick here if N/A.		
1.	Projected annual prescriptions/units to be sold?		
2.	Projected number of annual products users?		
3.	Any product ingredients/components imported?	□Yes	□No
	If <b>Yes</b> , please provide details.		
4.	Any products manufactured sold under others' labels?	□Yes	□No
	If <b>Yes</b> , please provide details.		
5.	Any products sold as ingredients/components for other products?	□Yes	□No
	If <b>Yes</b> , please provide details.		
6.	Any products manufactured outside the domestic country?	□Yes	□No
	If <b>Yes</b> , please provide details.		

7.	Any products approved for use by minors?	□Yes	$\square$ No
8.	Any products discontinued for safety reasons?	□Yes	□No
	If <b>Yes</b> , please provide details.		
9.	Any association with banned products?	□Yes	□No
	If <b>Yes</b> , please provide details.		
10.	How many product recalls has applicant had in the past 3 years?		
	Describe in detail any Class 1 recalls.		
11.	Indicate the top 3 products in terms of number of Adverse Event Reports where the product was associated with permanent injury, or hospitalisation outcome. Please provide copy of most recently completed Safety Report at these products.		
12.	Identify any product requiring the addition of a black box or other significant safety warning to existing labelin	ng or instr	uction
	manuals in the last 3 years.		
13.	Identify any safety surveillance team recommendations involving any of the following forms of remedial action be implemented or completed: product recall / withdrawal, black box warning label, "Healthcare Professional' studies, or expanded product monitoring.		
14.	What steps if any would the company take if applicant became aware of a pervasive off-label use of applicant's	products	?

15.	Please indicate known revenues from off-label use of your products.		
16.	Does the company allow any off-label information dissemination?	□Yes	□No
17.	Have there been any incidents of non-compliance regarding regulations concerning sales and marketing practices by either internal or external product sales personnel?	□Yes	□No
18.	How often are compliance audits performed on your internal and external sales staff?		
19.	Do compliance audits include follow-up discussions with physicians?	□Yes	□No
20.	What % of the company's advertising budget is allocated to Direct to Consumer (DTC) advertising?		
21.	Is there a required waiting period after product launch before DTC is conducted?	□Yes	□No
22.	What are the top 3 most expensive perks applicant provide to physicians?		
<ul><li>23.</li><li>24.</li></ul>	Does applicant have formal policy specifically prohibiting physical patient contact by internal and external product sales personnel?  Have there been any incidents of non-compliance in the last 3 years?  How often is formal and documented compliance training required of your internal and external sales force?	□Yes	□No
Sec	tion M - Operations Risk Management & Loss Control		
1.	Does applicant have a formalised Enterprise Risk / Safety Programme?	□Yes	□No
	If <b>Yes</b> , please provide name of person in charge of programme.		
2.	What are the main focal areas of your Enterprise Risk / Safety Programme? (Areas might include Code of Cond Biohazards, Disaster Recovery, etc.)	uct, Priva	cy,
3.	Does applicant require all new employees participate in training program that instructs them on all applicable company policies and procedures?	□Yes	□No

4.	Does applicant require Certificates of Insurance from all of applicants' suppliers and sub-contractors?	□Yes	□No
	What limits and terms does applicant require?		
5.	Are all risk management programmes and SOP's audited annually?	□Yes	□No
6.	Please indicate any risk management programmes and SOPs that are audited by independent non-governmental organisations / individuals?	□Yes	□No
7.	Indicate Industry Trade Associations Memberships.		
8.	Does applicant have a crisis management team in place?	□Yes	□No
9.	Does applicant have a full time risk manager on staff?	□Yes	□No
Sec	ction N - Premises / Operations		
	Please tick here if N/A.		
1.	Indicate which of the following applies to applicant's premises:		
	$\hfill \square$ Access is not allowed without card and/or authorised employee		
	☐ Front desk registration only		
	☐ No restricted access.		
2.	Indicate which of the following applies:		
	$\square$ Hazardous substances are kept outdoors or in a cut-off within approved containers		
	☐ Just in time supply levels		
	☐ Cut-off area with unapproved containers		
3.	Indicate how many gallons of hazardous substances are kept on site?	□Yes	□No
4.	Biohazard Lab Rating if applicable?		
5.	Do you have an animal facility or house animals?	□Yes	□No
6.	If applicable is the applicant in compliance with Hazardous Materials Regulations?	□Yes	□No
7.	Has applicant ever hired key employees from direct competitors?	□Yes	□No
8.	Does applicant ever do direct product comparisons against competitor products?	□Yes	□No

9.	Does applicant have any competitors making similar products?	□Yes	□No
10.	Does applicant have a formalised Privacy Policy in place?	□Yes	□No
	If <b>Yes</b> , when was it last updated and audited?		
Sec	tion O - Property		
	Please tick here if N/A.		
	wers to these industry-specific questions are requested as a supplement to standard industry (e.g. Acord) Prope ome applications.	erty and B	usiness
1.	<b>Change In Controlled Environment - Perishable Property</b> : Is perishable property (e.g. reagents, cell cultures, work-in-process or stock) with an estimated financial impact (replacement cost value plus resulting business income loss) in excess of \$250,000 stored at any single location? If <b>No</b> , proceed to question #7.	□Yes	□No
2.	What is the estimated maximum property damage and resulting business income loss which would result from a total loss of perishable property at any single location?		
3.	Is all perishable property monitored by a UL listed central station temperature alarm, programmed to activate in the event of both low and high temperatures, with protection operational at all times?	□Yes	□No
4.	Is temperature alarm effectiveness ensured through a regular maintenance programme with, at a minimum, annual scheduled testing?	□Yes	□No
5.	Are automatic, self-starting, non-electric back-up power units providing a minimum 24-hour power supply to all perishable property operational and load testing at least annually?	□Yes	□No
6.	Is a specific, pre-planned emergency response action plan in place and practiced at least annually to ensure rapid and effective intervention by trained personnel to failure of building support systems and resulting temperature emergencies?	□Yes	□No
7.	<b>Scientific Animals</b> : Are animals with replacement cost value (cost of purchasing a replacement animal plus any increase in the animal value as a result of your R&D operations, or selling price if animals are stock) in excess of \$100,000 housed at any single location? If <b>No</b> , proceed to question #14.	□Yes	□No
8.	What is the estimated maximum property damage loss which would result from a total loss of an animal colony at any single location?		
9.	Is access to all animal facilities restricted electronically to employees whose job functions require them to work in that area?	□Yes	□No
10.	Do the animal facilities have dedicated environmental control (including HVAC / air handling) systems, with an automatic, self starting back-up power source and UL listed central station alarms, with protection operational at all times?	□Yes	□No
11.	Are UL listed central station smoke alarms operational throughout the buildings where animals are housed, and are smoke dampers installed within the HVAC system to keep smoke which emanates from outside the animal lab from impacting the animals?	□Yes	□No
12.	Are the animal facilities monitored by a UL listed central station temperature alarm, programmed to activate in the event of both low and high temperatures, with protection operational at all times?	□Yes	□No

Are critical colonies separated into distinct facilities, or are embryonic cells of critical colonies cryogenically preserved off-site? $\Box$ Yes				□No		
<b>Research and Development Income</b> : Does the applicant anticipate earning any grants, endowments or financial contributions from third parties during the period of insurance, the payment of which is contingent upon attaining contractually stipulated R&D milestones? If <b>No</b> , proceed to question #17.				□No		
To the extent that insurance is requested for R&D Income described in #14 above, what is the total dollar value of the contracts which are expected to become payable during the period of insurance? Please note that a schedule of these contracts (title and R&D income value) must be reported to trigger R&D Income coverage under the policy. This information may be attached as an addendum to this application.				□No		
5. What is the largest Personal Property of Others value at any single location?						
7. Does applicant ship any perishable property, narcotics or live animals at their own risk?					□No	
ction P - Loss Hi	story & Potential	Loss				
olicy Period	Insurer	No. of Claims	Total Incurred	Total Paid L	oss Ratio	
otal aggregate cos	t (losses from groun	d up including defense	, deductibles, and SIR's	) for last five years.		
tach previous car	rier loss runs.					
1. Describe all incurred losses of \$10,000 or more						
Any claims not y	et reported?				□Yes	□No
If <b>Yes</b> , please pro	ovide details.					
	Research and I financial contrib upon attaining contribution attaini	Research and Development Inco financial contributions from third pa upon attaining contractually stipula  To the extent that insurance is requevalue of the contracts which are exp that a schedule of these contracts (ti coverage under the policy. This info  What is the largest Personal Propert  Does applicant ship any perishable pa To the extent that coverage in transpackaging, value and common carri  etion P - Loss History & Potential  Dicy Period Insurer  otal aggregate cost (losses from ground etach previous carrier loss runs.	Research and Development Income: Does the applican financial contributions from third parties during the period upon attaining contractually stipulated R&D milestones? If To the extent that insurance is requested for R&D Income or value of the contracts which are expected to become payability that a schedule of these contracts (title and R&D income or value at a schedule of these contracts (title and R&D income or value at a schedule of the policy. This information may be attached. What is the largest Personal Property of Others value at any Does applicant ship any perishable property, narcotics or literature.  To the extent that coverage in transit is requested for proper packaging, value and common carrier information.  Stion P - Loss History & Potential Loss  Dicy Period Insurer No. of Claims  Outlined Potential Loss  Sticy Period Insurer No. of Claims  Detail aggregate cost (losses from ground up including defense trach previous carrier loss runs.  Describe all incurred losses of \$10,000 or more	Research and Development Income: Does the applicant anticipate earning am financial contributions from third parties during the period of insurance, the payr upon attaining contractually stipulated R&D milestones? If No, proceed to questic To the extent that insurance is requested for R&D Income described in #14 above, value of the contracts which are expected to become payable during the period of that a schedule of these contracts (title and R&D income value) must be reported to coverage under the policy. This information may be attached as an addendum to What is the largest Personal Property of Others value at any single location?  Does applicant ship any perishable property, narcotics or live animals at their own. To the extent that coverage in transit is requested for property described in #17 ab packaging, value and common carrier information.  To the extent that coverage in transit is requested for property described in #17 ab packaging, value and common carrier information.  The extent that coverage in transit is requested for property described in #17 ab packaging, value and common carrier information.  The extent that coverage in transit is requested for property described in #17 ab packaging, value and common carrier information.  The extent that coverage in transit is requested for property described in #17 ab packaging, value and common carrier information.  The extent that coverage in transit is requested for property described in #17 ab packaging, value and common carrier information.  The extent that coverage in transit is requested for property described in #17 ab packaging, value and common carrier information.  The extent that coverage in transit is requested for property described in #17 ab packaging, value and common carrier information.	Research and Development Income: Does the applicant anticipate earning any grants, endowments or financial contributions from third parties during the period of insurance, the payment of which is contingent upon attaining contractually stipulated R&D milestones? If No, proceed to question #17.  To the extent that insurance is requested for R&D Income described in #14 above, what is the total dollar value of the contracts which are expected to become payable during the period of insurance? Please note that a schedule of these contracts (title and R&D Income adule) must be reported to trigger R&D Income coverage under the policy. This information may be attached as an addendum to this application.  What is the largest Personal Property of Others value at any single location?  Does applicant ship any perishable property, narcotics or live animals at their own risk?  To the extent that coverage in transit is requested for property described in #17 above, please provide full corpackaging, value and common carrier information.  **Total P- Loss History & Potential Loss**  **Total P- Loss History & Potential Loss**  Dicy Period Insurer No. of Claims Total Incurred Total Paid Incurred Insurer at a gargegate cost (losses from ground up including defense, deductibles, and SIR's) for last five years. Total aggregate cost (losses from ground up including defense, deductibles, and SIR's) for last five years. Total previous carrier loss runs.  Describe all incurred losses of \$10,000 or more	Research and Development Income: Does the applicant anticipate earning any grants, endowments or financial contributions from third parties during the period of insurance, the payment of which is contingent upon attaining contractually stipulated R&D milestones? If No, proceed to question #17.  To the extent that insurance is requested for R&D Income described in #14 above, which is the total dollar value of the contracts which are expected to become payable during the period of insurance? Please note that a schedule of these contracts (file and R&D income value) must be reported to trigger R&D income coverage under the policy. This information may be attached as an addendum to this application.  What is the largest Personal Property of Others value at any single location?  Does applicant ship any perishable property, narcotics or live animals at their own risk?  To the extent that coverage in transit is requested for property described in #17 above, please provide full commodity, packaging, value and common carrier information.  **Total Paid**  Itom P - Loss History & Potential Loss*  Atton P - Loss History & Potential Loss*  Atton P - Loss Gosses from ground up including defense, deductibles, and SIR's) for last five years.  And aggregate cost Gosses from ground up including defense, deductibles, and SIR's) for last five years.  And previous carrier loss runs.  Describe all incurred losses of \$10,000 or more  Any claims not yet reported?

3.	district litigation?					nulti-
4.						□No
uno	ler any policy (	equested in this Application of a Claim or potential Clain erage History	n is for underwriting purposes only n.	and does not constitute notice	to the Compa	uny
Po	olicy Period	Primary & Excess Limits	Carriers	Occurrence/Claims Made	Retro Date	
1.		nt have any outstanding lose	s control recommendations with a	pplicant's current carrier?	□Yes	□No
	, <b>F</b>	F				
2.	Has applicant's insurance ever been canceled or non-renewed by a carrier?  If <b>Yes</b> , please provide details.			□Yes	□No	
3.	Any of your products, clinical trials, or services specifically excluded on your existing policy? $\Box$ Yes $\Box$ N			□No		
	If <b>Yes</b> , please	provide details.				
4.	Have you had retro date?	d concurrent claims made ir	nsurance for the insurance you are	requesting back to your stated	□Yes	□No

#### Section R - Insurance Requested

Coverage	Limits Requested	Deductible/SIR Requested
Premises & Operations Liability		
Products & Completed Operations Liability		
Professional Liability (E&O Financial Injury)		
Property		
Other		
Details		

#### **Applicant Acknowledgement**

Information or data contained in or submitted in connection with this application (or otherwise to any of the member insurers of Chubb group of insurance companies ("Chubb") in connection with the underwriting process) does not constitute notice of an occurrence, wrongful act, claim, suit or other circumstance and does not satisfy any of the reporting notification or other provisions of any policy. All such notices must be given separately in accordance with the applicable policy conditions.

For the purposes of this application, the above-signed officer of all person(s) and organisation(s) proposed for this insurance declares and acknowledges by executing this application that, no alterations were made to this application (other than sections reserved for answers), he/she has reviewed this application and the statements contained therein with his/her Chief Executive Officer, Chief Financial Officer, Chief Operating Officer or their equivalents, and that to the best of their knowledge and belief, after reasonable inquiry, the statements in this application, and in any attachments, are true and complete for all persons or organisations applying for insurance under this application. Chubb is authorised to make any inquiry in connection with this application. Signing this application shall not constitute a binder or obligate Chubb to complete this insurance, but it is agreed this application shall be the basis upon which a policy may be issued. If the statements in this application or in any attachment change materially before the effective date of any proposed policy, the applicant must notify Chubb, and Chubb may modify or withdraw any quotation.

Authorised Signature of Applicant	Submitted By (Insurance Agent)
Date	Insurance Agency
Print Name	Address
Title	Date
	Contact Us  Chubb Insurance Singapore Limited
Applicant	138 Market Street #11-01 CapitaGreen Singapore 048946 O +65 6398 8000 F +65 6298 1055
Authorised Agent (Please Print Name)	E CustomProducts.SG@chubb.com www.chubb.com/sg
Authorised Agent (Signature)	-
Title	-
Date	-

# Chubb. Insured.<sup>sm</sup>

Published 06/2016 Page 19 of 19

<sup>&</sup>lt;sup>©</sup> 2016 Chubb. Coverages underwritten by one or more subsidiary companies. Not all coverages available in all jurisdictions. Chubb <sup>\*</sup> and its respective logos, and Chubb. Insured. <sup>SM</sup> are protected trademarks of Chubb.